Bazedoxifene/Conjugated Estrogen
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vaginal Atrophy
Conditions
Vaginal Atrophy
Trial Timeline
Oct 1, 2005 → Mar 1, 2007
NCT ID
NCT00238732About Bazedoxifene/Conjugated Estrogen
Bazedoxifene/Conjugated Estrogen is a phase 3 stage product being developed by Pfizer for Vaginal Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT00238732. Target conditions include Vaginal Atrophy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00238732 | Phase 3 | Completed |
| NCT00234819 | Phase 3 | Completed |
Competing Products
19 competing products in Vaginal Atrophy